Analytical Data
-
基因名
CYFRA21-1
- Application
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P08727
-
表达区间
Asp244~Leu400
-
分子量
22kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYFRA21-1 is a fragment of cytokeratin 19, a type of protein that plays a crucial role in the structural integrity of epithelial cells. Its significance in clinical diagnostics stems from its elevated levels in various malignancies, particularly non-small cell lung cancer (NSCLC). Research has established that CYFRA21-1 serves as a valuable tumor marker, helping in early detection, monitoring treatment response, and assessing prognosis in lung cancer patients. Recent studies have focused on the development of recombinant CYFRA21-1 protein to enhance the sensitivity and specificity of diagnostic assays. This recombinant form allows for standardized testing methods, facilitating comparison across different laboratories. Additionally, it enables further research into the protein's biological functions and interactions, potentially unveiling new therapeutic targets. The integration of recombinant CYFRA21-1 in clinical settings aims to improve patient outcomes and advance personalized medicine approaches in oncology. As such, ongoing investigations into its utility and mechanisms of action continue to be a focal point in cancer research, holding promise for better diagnostic and therapeutic strategies in lung cancer and beyond.
